GlassScriptPhysician profile
Alejandra Pena
NPI 1285216622
$5,011.32
in general payments reported to CMS, 2019-2025
47 companies · $2,616 in 2025
The $2,616 reported for 2025 was more than what 96% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $280 · 2024: $2,115 · 2025: $2,616.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,995 · Education: $15.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,995.33 |
| Education | $15.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $432.26 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $421.87 | 2023-2025 | Lynparza, Datroway, Calquence |
| Pfizer INC. | $366.14 | 2024-2025 | |
| Janssen Biotech, INC. | $349.45 | 2024-2025 | Darzalex, Tecvayli, Rybrevant |
| Daiichi Sankyo INC. | $328.25 | 2024-2025 | Enhertu, Datroway |
| Merck Sharp & Dohme LLC | $317.45 | 2023-2025 | Keytruda, Lynparza, Welireg |
| Takeda Pharmaceuticals U.S.A., INC. | $247.68 | 2023-2025 | Fruzaqla, Iclusig, Ninlaro |
| Incyte Corporation | $188.97 | 2023-2025 | Jakafi, Monjuvi, Zynyz |
| Abbvie INC. | $164.65 | 2024-2025 | |
| Eisai INC. | $162.89 | 2024-2025 | |
| Sobi, INC | $153.95 | 2023-2025 | |
| Tempus Ai, INC | $136.25 | 2024 | Xt Cdx |
| Genentech USA, INC. | $109.37 | 2024-2025 | Polivy, Tecentriq Hybreza, Phesgo |
| Rigel Pharmaceuticals, INC. | $107.48 | 2024 | Tavalisse, Rezlidhia |
| Lilly USA, LLC | $103.67 | 2023-2025 | Jaypirca, Verzenio, Retevmo |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alejandra Pena listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.